Media headlines about Sunshine Heart (NASDAQ:CHFS) have been trending somewhat positive on Wednesday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sunshine Heart earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.0976730788332 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of brokerages have recently commented on CHFS. Zacks Investment Research raised Sunshine Heart from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a research note on Wednesday, December 6th. ValuEngine raised Sunshine Heart from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 31st.
Sunshine Heart (CHFS) traded up $0.05 during midday trading on Wednesday, hitting $3.56. The stock had a trading volume of 139,600 shares, compared to its average volume of 223,866. The company has a market capitalization of $6.31, a P/E ratio of -0.02 and a beta of 2.25. Sunshine Heart has a 52-week low of $2.87 and a 52-week high of $270.00.
About Sunshine Heart
CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with MarketBeat.com's FREE daily email newsletter.